C07K 2317/10
Characterized by their source of isolation or production
Official title: characterized by their source of isolation or production
C07K2317/10 (Characterized by their source of isolation or production) appears on 2,447 US grants and 4,339 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,447
- Published applications
- 4,339
- Assignees
- 1,409
- Inventors
- 7,112
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 9 | 0 |
| 1999 | 8 | 0 |
| 2000 | 8 | 0 |
| 2001 | 10 | 0 |
| 2002 | 10 | 18 |
| 2003 | 13 | 26 |
| 2004 | 13 | 34 |
| 2005 | 9 | 42 |
| 2006 | 20 | 52 |
| 2007 | 12 | 37 |
| 2008 | 15 | 49 |
| 2009 | 32 | 74 |
| 2010 | 40 | 75 |
| 2011 | 45 | 109 |
| 2012 | 53 | 143 |
| 2013 | 70 | 172 |
| 2014 | 99 | 248 |
| 2015 | 161 | 306 |
| 2016 | 201 | 407 |
| 2017 | 213 | 320 |
| 2018 | 200 | 257 |
| 2019 | 187 | 298 |
| 2020 | 224 | 226 |
| 2021 | 154 | 268 |
| 2022 | 152 | 240 |
| 2023 | 129 | 201 |
| 2024 | 136 | 294 |
| 2025 | 125 | 236 |
| 2026 | 85 | 207 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Compositions and methods for modulating FLRT3 mediated signal transduction6 Oct 2026US 12,753,229 B2Nextcure, Inc.
- Manufacturing methods for producing anti-IL12/IL23 antibody compositions29 Sep 2026US 12,747,289 B2Janssen Biotech, Inc.
- Human IL-33 antibodies, preparation method and conjugates thereof and method of use thereof for treatment22 Sep 2026US 12,742,005 B2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Binding molecules for the treatment of cancer22 Sep 2026US 12,742,022 B2Boehringer Ingelheim International GmbH
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308247 A1Novartis AG
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308248 A1Novartis AG
- Anxiolytic therapy8 Oct 2026US 2026/0308253 A1
- Methods and means for the production of ig-like molecules8 Oct 2026US 2026/0308655 A1Merus N.V.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Expression of functional antibody fragments507US 5,648,237 AGenentech, Inc. · 1997
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012